Abstract
It has now been 30 years since the first epidemiologic report linked menopausal estrogen therapy—the exogenous estrogens that, along with progestins, came to be known as “hormone replacement therapy”—with an increased risk of breast cancer ([1][1]). Today, the body of evidence on this
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
